Eli Lilly reported a strong Q1 2026 with 55.55% revenue growth to $19.8 billion, driven by blockbuster drugs Mounjaro and Zepbound, and raised its full-year revenue guidance. The company is investing aggressively in AI drug discovery and acquisitions, signaling growth momentum. Pfizer, meanwhile, posted a 1.2% revenue decline in Q4 2025, still recovering from COVID-related revenue drops, with growth in non-COVID products but steep declines in vaccines and treatments like Comirnaty and Paxlovid. Pfizer’s M&A strategy focuses on replacing lost revenue, while Lilly’s approach compounds future growth. For long-term investors, Lilly appears stronger despite a higher valuation, while Pfizer offers a higher dividend yield but faces patent cliff challenges.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
